Alexei A. Grom, MD

Research Director, Division of Rheumatology
Professor, UC Department of Pediatrics

alexei.grom@cchmc.org
Board Certified

Burnet Campus

Make An Appointment

New PatientsSchedule OnlineSchedule Online

Existing PatientsMyChart SchedulingMyChart Scheduling

Call Us to ScheduleAppointments1-513-636-3200Appointments

My Lab

Visit the Grom-Thorton LabVisit the Grom-Thorton Lab

About

Biography

My early work with outstanding mentors, who were pediatric rheumatologists, led me to pursue my clinical and research interests. During my fellowship, the unfortunate death of a patient from macrophage activation syndrome (MAS) prompted me to further study this life-threatening complication of systemic juvenile idiopathic arthritis.

Currently, I focus on identifying risk factors and new therapeutic targets in MAS. Our transnational studies have identified interferon gamma (INF), a dimerized soluble cytokine, as a therapeutic target in patients suffering from MAS. This discovery provided the rationale for a new clinical trial that is currently underway.

My research is funded by the National Institutes of Health (NIH) and the Systemic Juvenile Idiopathic Arthritis (SJIA) Foundation. I have also received research grants from Sobi, Novartis and AB2Bio.

Services and Specialties

Rheumatology, Lupus, Rare Lung Diseases

Research Areas

Rheumatology

Additional Languages

French, Russian

Location

Burnet Campus

3333 Burnet Ave
Cincinnati, OH 45229

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Brunner, HI; Schulert, GS; Sproles, A; Thornton, S; Cornejo, GV; Antón, J; Cuttica, R; Henrickson, M; Foeldvari, I; Kingsbury, DJ; Lovell, DJ; Martini, A; Ruperto, N; Grom, AA. Arthritis Research and Therapy. 2024; 26:125.

Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis. Correia Marques, M; Rubin, D; Shuldiner, EG; Datta, M; Schmitz, E; Gutierrez Cruz, G; Patt, A; Bennett, E; Grom, A; Foell, D; Woo, P; Yeung, RS M; Zeft, AS; Zeggini, E. Arthritis and Rheumatology. 2024; 76:1566-1572.

Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Lovell, DJ; Tzaribachev, N; Henrickson, M; Simonini, G; Griffin, TA; Alexeeva, E; Bohnsack, JF; Zeft, A; Horneff, G; Vehe, RK; Costanzo, D; Rennebohm, R; Waugaman, B; Brodus, E. Rheumatology. 2024; 63:SI195-SI206.

Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Huang, Y; Sompii-Montgomery, L; Patti, J; Pickering, A; Yasin, S; Do, T; Baker, E; Gao, D; Abdul-Aziz, R; Behrens, EM; Ting, T; Grom, AA; Towe, C; Schulert, GS. Arthritis Care and Research. 2024; 76:328-339.

Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Peng, J; Dönnes, P; Ardoin, SP; Schanberg, LE; Lewandowski, L; Ardoin, S; Dewitt, EM; Rabinovich, CE; Ellis, J; Mieszkalski, K; Paepke-Tollefsrud, DE; Robinson, G; Jury, EC; Ciurtin, C. Arthritis and Rheumatology. 2024; 76:455-468.

The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Schulert, G; Vastert, SJ; Grom, AA. Pediatric Rheumatology Online Journal. 2024; 21:87.

Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Grom, AA; Canna, SW; Abu-Arja, RF; Sinha, R; Peixoto, L; Cannizzaro, E; Chandrakasan, S; Driest, K; Marsh, R; Neven, B; Schulert, G; Silva, JM F; Wall, D; Zeilhofer, U. Pediatric Rheumatology Online Journal. 2024; 21:86.

The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. de Benedetti, F; Grom, AA; Brunner, H. Pediatric Rheumatology Online Journal. 2024; 21:150.

Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Erkens, RG A; Calis, JJ A; Verwoerd, A; De Roock, S; Ter Haar, NM; Den Engelsman, G; Van der Veken, LT; Ernst, RF; Van Deutekom, HW M; Pickering, A; Schulert, GS; Grom, AA; Van Loosdregt, J; Vastert, SJ. Arthritis and Rheumatology. 2024; 76:119-129.

Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. Verweyen, EL; Thakkar, K; Dhakal, S; Baker, E; Chetal, K; Schnell, D; Canna, S; Grom, AA; Salomonis, N; Schulert, GS. The Journal of Clinical Investigation. 2023; 133:e166741.

From the Blog

Rare Diseases

Clinical Trial Success Caps Long Journey for HLH Treatment

Alexei A. Grom, MD, Michael B. Jordan, MD3/22/2021

Autoimmune Disorders

Aggressive Screening Needed to Detect sJIA Lung Complication

Alexei A. Grom, MD, Grant Schulert, MD, PhD10/29/2019

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6

Overall Patient Rating

Our Response to the IV Fluid Shortage